Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma

Area of Science:

• Oncology
• Surgical Oncology
• Breast Cancer Research

Background:

• Early-stage breast carcinoma treatment involves primary tumor removal and axillary lymph node evaluation.
• Sentinel lymph node dissection (SLND) is an alternative to axillary lymph node dissection (ALND) for clinically node-negative patients, offering fewer side effects.
• A key concern with SLND alone is the potential for increased axillary lymph node recurrence.

Purpose of the Study:

• To evaluate the rate of axillary lymph node recurrence in early-stage breast carcinoma patients treated with SLND without concomitant ALND.
• To assess the safety and efficacy of SLND as a standalone procedure for axillary staging.

Main Methods:

• Retrospective analysis of 700 consecutive early-stage breast carcinoma cases undergoing SLND only.
• Data collected from the oncology registry at Park Nicollet Health Services between January 28, 1999, and December 31, 2003.
• Exclusion of 52 patients with ductal carcinoma in situ from the final analysis.

Main Results:

• Axillary lymph node recurrence was observed in only 4 out of 647 patients (0.62%) after a median follow-up of 33 months.
• All recurrences were isolated to the axilla and amenable to surgical intervention.
• The low recurrence rate suggests SLND is effective in axillary staging for selected breast cancer patients.

Conclusions:

• Sentinel lymph node dissection (SLND) alone is associated with a very low rate of axillary lymph node recurrence in early-stage breast carcinoma.
• These findings support SLND as a safe and effective method for axillary staging, comparable to existing literature.
• The study reinforces the utility of SLND in minimizing surgical morbidity while adequately staging the axilla.